Carthera
France
- PARIS, IDF
- 27/06/2023
- Series B
- $41,077,875
Carthera® is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat a wide range of severe brain disorders.
Carthera® has developed a proprietary device called SonoCloud®- a groundbreaking medical device that emits ultrasound to temporarily increase the permeability of the blood vessels in the brain.
By using SonoCloud®, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases: oncology indications (glioblastoma, brain metastasis) or neurodegenerative diseases (such as Alzheimer’s Disease, ALS).
The products developed by Carthera® are in clinical or preclinical evaluation (not FDA or CE approved) and are not available for sale.
- Industry Medical Equipment Manufacturing
- Website https://carthera.eu/
- LinkedIn https://www.linkedin.com/company/carthera/
EnerVenue | $300,000,000 | (Apr 3, 2026)
Acurion, Inc. | $4,300,000 | (Apr 3, 2026)
Gander Robotics | $1,100,000 | (Apr 3, 2026)
daydream | $15,000,000 | (Apr 3, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Alien | $7,100,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)
Sona(UK) | $45,000,000 | (Apr 2, 2026)
Linx Security | $50,000,000 | (Apr 2, 2026)
Earlyasset | $2,000,000 | (Apr 2, 2026)
Rowan(US) | $3,300,000 | (Apr 2, 2026)
Whirl AI | $8,900,000 | (Apr 2, 2026)